175 related articles for article (PubMed ID: 30714079)
1. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.
Johansson PA; Stark A; Palmer JM; Bigby K; Brooks K; Rolfe O; Pritchard AL; Whitehead K; Warrier S; Glasson W; Hayward NK
Immunogenetics; 2019 May; 71(5-6):433-436. PubMed ID: 30714079
[TBL] [Abstract][Full Text] [Related]
2. Germline loss-of-function variants in MBD4 are rare in Finnish patients with uveal melanoma.
Repo P; Jäntti JE; Järvinen RS; Rantala ES; Täll M; Raivio V; Kivelä TT; Turunen JA
Pigment Cell Melanoma Res; 2020 Sep; 33(5):756-762. PubMed ID: 32421892
[TBL] [Abstract][Full Text] [Related]
3. Germline MBD4 Mutations and Predisposition to Uveal Melanoma.
Derrien AC; Rodrigues M; Eeckhoutte A; Dayot S; Houy A; Mobuchon L; Gardrat S; Lequin D; Ballet S; Pierron G; Alsafadi S; Mariani O; El-Marjou A; Matet A; Colas C; Cassoux N; Stern MH
J Natl Cancer Inst; 2021 Jan; 113(1):80-87. PubMed ID: 32239153
[TBL] [Abstract][Full Text] [Related]
4. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.
Rodrigues M; Mobuchon L; Houy A; Fiévet A; Gardrat S; Barnhill RL; Popova T; Servois V; Rampanou A; Mouton A; Dayot S; Raynal V; Galut M; Putterman M; Tick S; Cassoux N; Roman-Roman S; Bidard FC; Lantz O; Mariani P; Piperno-Neumann S; Stern MH
Nat Commun; 2018 May; 9(1):1866. PubMed ID: 29760383
[TBL] [Abstract][Full Text] [Related]
5. Evolutionary Routes in Metastatic Uveal Melanomas Depend on
Rodrigues M; Mobuchon L; Houy A; Alsafadi S; Baulande S; Mariani O; Marande B; Ait Rais K; Van der Kooij MK; Kapiteijn E; Gassama S; Gardrat S; Barnhill RL; Servois V; Dendale R; Putterman M; Tick S; Piperno-Neumann S; Cassoux N; Pierron G; Waterfall JJ; Roman-Roman S; Mariani P; Stern MH
Clin Cancer Res; 2019 Sep; 25(18):5513-5524. PubMed ID: 31227496
[TBL] [Abstract][Full Text] [Related]
6. Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants.
Villy MC; Le Ven A; Le Mentec M; Masliah-Planchon J; Houy A; Bièche I; Vacher S; Vincent-Salomon A; Dubois d'Enghien C; Schwartz M; Piperno-Neumann S; Matet A; Malaise D; Bubien V; Lortholary A; Ait Omar A; Cavaillé M; Stoppa-Lyonnet D; Cassoux N; Stern MH; Rodrigues M; Golmard L; Colas C
J Natl Cancer Inst; 2024 Apr; 116(4):580-587. PubMed ID: 38060262
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
8. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.
Saint-Ghislain M; Derrien AC; Geoffrois L; Gastaud L; Lesimple T; Negrier S; Penel N; Kurtz JE; Le Corre Y; Dutriaux C; Gardrat S; Barnhill R; Matet A; Cassoux N; Houy A; Ramtohul T; Servois V; Mariani P; Piperno-Neumann S; Stern MH; Rodrigues M
Eur J Cancer; 2022 Sep; 173():105-112. PubMed ID: 35863105
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
10. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
Palles C; West HD; Chew E; Galavotti S; Flensburg C; Grolleman JE; Jansen EAM; Curley H; Chegwidden L; Arbe-Barnes EH; Lander N; Truscott R; Pagan J; Bajel A; Sherwood K; Martin L; Thomas H; Georgiou D; Fostira F; Goldberg Y; Adams DJ; van der Biezen SAM; Christie M; Clendenning M; Thomas LE; Deltas C; Dimovski AJ; Dymerska D; Lubinski J; Mahmood K; van der Post RS; Sanders M; Weitz J; Taylor JC; Turnbull C; Vreede L; van Wezel T; Whalley C; Arnedo-Pac C; Caravagna G; Cross W; Chubb D; Frangou A; Gruber AJ; Kinnersley B; Noyvert B; Church D; Graham T; Houlston R; Lopez-Bigas N; Sottoriva A; Wedge D; ; ; ; Jenkins MA; Kuiper RP; Roberts AW; Cheadle JP; Ligtenberg MJL; Hoogerbrugge N; Koelzer VH; Rivas AD; Winship IM; Ponte CR; Buchanan DD; Power DG; Green A; Tomlinson IPM; Sampson JR; Majewski IJ; de Voer RM
Am J Hum Genet; 2022 May; 109(5):953-960. PubMed ID: 35460607
[TBL] [Abstract][Full Text] [Related]
11. [MBD4 inactivation induces a new mutator phenotype in cancers].
Rodrigues M; Mobuchon L; Houy A; Derrien AC; Stern MH
Bull Cancer; 2018 Sep; 105(9):736-737. PubMed ID: 30032956
[No Abstract] [Full Text] [Related]
12. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
13. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
Cebulla CM; Binkley EM; Pilarski R; Massengill JB; Rai K; Liebner DA; Marino MJ; Singh AD; Abdel-Rahman MH
Ophthalmic Genet; 2015 Jun; 36(2):126-31. PubMed ID: 25687217
[TBL] [Abstract][Full Text] [Related]
14. Oncologist-led germline genetic testing for uveal melanoma.
Gillies B; Krema H; Chao A; Lando L; Farncombe KM; Butler M; Altomare F; Kim RH
Ophthalmic Genet; 2023 Jun; 44(3):253-261. PubMed ID: 36974392
[TBL] [Abstract][Full Text] [Related]
15. MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes.
Terradas M; Gonzalez-Abuin N; García-Mulero S; Viana-Errasti J; Aiza G; Piulats JM; Brunet J; Capellá G; Valle L
Eur J Hum Genet; 2023 Oct; 31(10):1185-1189. PubMed ID: 37402954
[TBL] [Abstract][Full Text] [Related]
16. The genetic basis of uveal melanoma.
Nielsen M; Dogrusöz M; Bleeker JC; Kroes WG; van Asperen CA; Marinkovic M; Luyten GP; Jager MJ
J Fr Ophtalmol; 2015 Jun; 38(6):516-21. PubMed ID: 25976137
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
18. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
19. Hereditary uveal melanoma: a report of a germline mutation in BAP1.
Höiom V; Edsgärd D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Genes Chromosomes Cancer; 2013 Apr; 52(4):378-84. PubMed ID: 23341325
[TBL] [Abstract][Full Text] [Related]
20. Lack of GNAQ germline mutations in uveal melanoma patients with high risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BB; Davidorf FH
Fam Cancer; 2011 Jun; 10(2):319-21. PubMed ID: 21072599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
